Synairgen is a drug discovery and development company specialising in respiratory diseases with a focus on asthma and chronic obstructive pulmonary disease (COPD). These diseases are rapidly growing causes of morbidity and mortality worldwide and represent an increasing and largely unmet medical need.

At Synairgen, we focus on the discovery of new drugs which address the underlying causes rather than the symptoms of asthma and COPD. We aim to do this both in-house and via collaborations with industry partners, using our advanced in vitro cell models of human disease. The founding technology stems from at least twenty years of development in the laboratories at the University of Southampton led by Professors Stephen Holgate, Donna Davies and Ratko Djukanovic.